Among 4 analysts covering Alphatec Holdings Inc. (NASDAQ:ATEC), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Alphatec Holdings Inc. had 6 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 22. The company was downgraded on Friday, August 7 by Zacks. The company was downgraded on Wednesday, August 5 by Canaccord Genuity. The firm has “Underperform” rating by Northland Capital given on Monday, March 14. See Alphatec Holdings, Inc. (NASDAQ:ATEC) latest ratings:
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
16/10/2017 Broker: Lake Street Rating: Buy New Target: $7 Initiates Coverage On
Analysts expect Canadian Natural Resources Limited (NYSE:CNQ) to report $0.25 EPS on March, 1.They anticipate $0.13 EPS change or 34.21% from last quarter’s $0.38 EPS. CNQ’s profit would be $301.27 million giving it 30.41 P/E if the $0.25 EPS is correct. After having $0.08 EPS previously, Canadian Natural Resources Limited’s analysts see 212.50% EPS growth. The stock decreased 0.78% or $0.24 during the last trading session, reaching $30.41. About 218,561 shares traded. Canadian Natural Resources Limited (NYSE:CNQ) has risen 10.32% since February 14, 2017 and is uptrending. It has underperformed by 6.38% the S&P500.
Canadian Natural Resources Limited acquires, explores for, develops, produces, markets, and sells crude oil, natural gas, and natural gas liquids . The company has market cap of $36.65 billion. The firm offers light and medium crude oil, primary heavy crude oil, Pelican Lake heavy crude oil, bitumen, and synthetic crude oil (SCO). It has a 17.23 P/E ratio. The Company’s midstream assets include two crude oil pipeline systems; and a 50% working interest in an 84-megawatt cogeneration plant at Primrose.
Among 14 analysts covering Canadian Natural Resources Limited (NYSE:CNQ), 10 have Buy rating, 0 Sell and 4 Hold. Therefore 71% are positive. Canadian Natural Resources Limited had 31 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, June 16 by RBC Capital Markets. The firm has “Neutral” rating given on Friday, July 21 by Citigroup. The firm earned “Equal-Weight” rating on Tuesday, January 12 by Morgan Stanley. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, July 19. The stock has “Buy” rating by Citigroup on Friday, June 17. JP Morgan maintained the shares of CNQ in report on Tuesday, December 15 with “Neutral” rating. Bank of America initiated the shares of CNQ in report on Friday, August 19 with “Buy” rating. The firm has “Market Perform” rating by Wells Fargo given on Wednesday, February 7. JP Morgan downgraded the stock to “Overweight” rating in Wednesday, August 26 report. Morgan Stanley maintained the stock with “Overweight” rating in Wednesday, January 24 report.
Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, manufacture, and marketing of products for the surgical treatment of spine disorders. The company has market cap of $65.86 million. The Company’s product and procedural portfolio, as well as pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. It currently has negative earnings. The firm offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, XYcor Expandable Spinal Spacer System, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and thoracolumbar fixation products, such as Arsenal Degenerative, Arsenal Deformity, Arsenal CBx Cortical Bone Fixation, and Zodiac Degenerative Spinal Fixation systems.
The stock increased 1.22% or $0.04 during the last trading session, reaching $3.32. About 1,025 shares traded. Alphatec Holdings, Inc. (NASDAQ:ATEC) has declined 6.76% since February 14, 2017 and is downtrending. It has underperformed by 23.46% the S&P500.